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Abstract. Circulating tumor cells (CTCs) in the blood of 
cancer patients have been demonstrated to be of prognostic 
value regarding metastasis and survival. The CellSearch® 
system has been certified for the detection of CTCs and as a 
prognostic tool in patients with metastatic breast, colon and 
prostate cancer. Few studies have evaluated the detection of 
CTCs originating from esophagogastric or pancreatic cancer 
with the CellSearch® system. In the present small pilot study, 
a total of 16 patients with either esophagogastric (n=8) or 
pancreatic (n=8) adenocarcinomas at various disease stages 
were randomly screened and included. A total of 7.5 ml of 
blood was drawn from each patient and analyzed for CTCs 
using the CellSearch® device. CTCs could be detected in 
1 out of 8 patients (12.5%) with esophagogastric and in 7 out 
of 8 patients (87.5%) with pancreatic cancer. The prelimi-
nary data obtained from this observational feasibility study 
suggested that the CellSearch® system may become a valuable 
tool for the detection of CTCs in patients with pancreatic 
adenocarcinoma, whereas the usefulness in patients with 
early-stage esophagogastric adenocarcinoma may be limited. 
This study clearly points towards a requirement for larger 
studies focusing on patients with pancreatic adenocarcinoma 
at various disease stages and assessing CTCs, whereas patients 
with esophagogastric adenocarcinomas should be part of 
further pilot studies.
Introduction
Adenocarcinomas of the esophagogastric junction (AEGJ) are 
of particular interest nowadays, as numerous studies from a 
range of industrialized Western countries have reported an 
increased incidence of adenocarcinomas of the esophagus and 
the cardia over the last 30 years, which is in contrast to the 
decreasing incidence of gastric cancer (1). These tumors are 
sub‑classified based on the anatomical‑topographical location 
of the tumor center according to the Siewert classification (2). 
AEGJ are currently staged according to the 7th edition of 
the Union for International Cancer Control/American Joint 
Committee on Cancer Tumor-Node-Metastasis (TNM) clas-
sification system (3). The overall survival (OS) rate has been 
reported to be 15-20% and the 5-year survival rates are ~40% 
following a complete (R0) resection (4,5).
Exocrine tumors are the most common type of pancreatic 
cancer, the majority presenting with the histological charac-
teristics of adenocarcinoma, resembling the pancreatic ductal 
cell (6). Among all cancer-related mortalities in the United 
States, malignant tumors of the pancreas rank fourth (7) and 
the overall (global) mortality rate is 98% (8). As a number of 
patients already present with advanced disease or even metas-
tasis at the time of diagnosis, only 10-20% of the patients are 
eligible for surgical resection. These patients have a 5-year 
survival rate of 10-24% for cases with R0 resection (9,10). 
This poor prognosis reflects the particularly aggressive 
and lethal nature of this type of cancer. Recurrence rates 
of almost 80% after have also been observed following R0 
resections (10).
Over the past decade, the detection of circulating tumor 
cells (CTCs) in the peripheral blood of cancer patients has 
gained more and more attention. An increasing number of 
trials have suggested that those patients who tested positive 
for CTCs experienced shorter survival times than those who 
tested negative for CTCs. For example, primary breast cancer 
patients who tested ‘positive’ for CTCs (i.e., ≥5 CTCs/7.5 ml 
of blood) had a shorter progression-free survival (PFS) time 
(2.7 vs. 7.0 months) and a shorter OS time (10.1 vs. >18 months) 
compared with those who tested ‘negative’ (i.e., <5 CTC/7.5 ml 
of blood) (11,12).
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The CellSearch® system is a validated and widely accepted 
device for the detection of CTCs in human peripheral 
blood (13), which has already gained approval by the Amer-
ican Food and Drug Administration (FDA) for the detection 
of CTCs and as a prognostic tool to predict PFS and OS in 
patients with metastatic disease originating from the prostate, 
breasts and colon (14).
However, limited data regarding the feasibility of detection 
of CTCs in patients with pancreatic or esophagogastric adeno-
carcinoma is available. Therefore, the aim of the present small 
study was to determine the feasibility and frequency of the 
detection of CTCs by applying the CellSearch® system in these 
two tumor entities, with the primary endpoint being the detec-
tion of CTCs (yes or no). We hypothesized that CellSearch® 
would be able to detect CTCs in the blood of patients from the 
two disease groups regardless of the stage of the disease.
Patients and methods
Study population. Following approval by the local ethics 
committee (Kantonale Ethikkommission Zurich, Zurich, 
Switzerland), 16 consecutive patients (>18 years old) with either 
AEGJ or pancreatic cancer (8 patients each) at various disease 
stages and undergoing various treatments were included in the 
study. Patients were only excluded in instances of any ethical 
contraindications or the inability of the patient to understand 
the language of the center where the study was performed 
(i.e., German). Written informed consent was obtained from all 
patients.
Detection of CTCs using the CellSearch system. In total, 7.5 ml 
of blood was drawn from each patient into CellSave Preserva-
tive tubes (Janssen Diagnostics, Raritan, NJ, USA). Blood 
collection from pancreatic cancer patients was conducted 
during an office visit. For esophagogastric cancer patients, 
two different time points were established to collect the blood 
samples: i) Prior to chemotherapy or surgery (if eligible; t0); 
and ii) 60 min after the surgical en bloc resection of the tumor 
(if eligible; t1). Details about the timing of blood collection for 
each patient are provided in Table I.
CTC analysis was conducted in accordance with the manu-
facturer's instructions (Janssen Diagnostics). Briefly, the cells 
were initially centrifuged at room temperature at 800 x g for 
10 min. Subsequently, further processing of the blood cells 
was performed with the automated CellTracks® Autoprep® 
System (Janssen Diagnostics), which uses ferrofluid nanopar-
ticles coated with an antibody against epithelial cell adhesion 
molecule (EpCAM) for the enrichment of CTC, as well as 
fluorescent staining against cytokeratin and the cell surface 
marker cluster of differentiation 45 (CD45). Cell nuclei were 
stained using 4',6-diamidino-2-phenylindole. Finally, cells 
captured in the MagNest cassette were analyzed with Cell-
Tracks Analyzer II®. Nucleated cells, which stained positive 
for cytokeratin and negative for CD45 (Fig. 1) were counted as 
CTCs by two specially trained individuals.
Results
Patient characteristics. A total of 8 patients (3 females and 
5 males), with locally-advanced (cT2-4, N any, M any) AEGJ 
and a median age of 67 years (range, 41-82 years) were 
included in the study (Table I). Loco-regional lymph nodes 
(cN+) were detected in 7 out of 8 (87.5%) patients and distant 
metastases (lymph node or bone) were present in 2 out of 
8 patients (25.0%) (Table I). Additionally, 4 out of 8 (50.0%) 
patients received chemotherapy prior to the blood collection 
for CTC detection. Of these, 2 patients received 4 cycles of a 
5‑fluorouracil, leucovorin, oxaliplatin and docetaxel regimen, 
1 patient underwent pre-treatment with 5 cycles of carbo-
platin and paclitaxel, and 1 patient received 4 weekly doses 
of a cisplatin and docetaxel-based regimen. Of the 8 patients, 
2 (25.0%) were subjected to concurrent pre-operative local 
radiotherapy (42-45 Gy), and 3 (37.5%) had undergone a diag-
nostic laparoscopy during the staging process (Table I).
The characteristics of the patients with pancreatic 
adenocarcinoma are summarized in Table II. For this group, 
8 consecutive patients (2 females and 6 males) at different 
disease stages were enrolled in the study. The patients 
had a median age of 60 years at the time of study entry 
(range, 35-73 years). In total, 6 out of 8 (75.0%) patients 
presented with loco-regional lymph node metastases and 4 out 
of 8 (50.0%) patients exhibited distant metastases, as speci-
fied in Table II. With regard to treatment, 5 out of 8 patients 
(62.5%) received chemotherapy prior to CTC detection. The 
majority of patients received the folinic acid, 5‑fluorouracil, 
irinotecan and oxaliplatin (FOLFIRINOX) regimen; in 
4 patients, a median of 8 cycles (range, 1-13 cycles) were used, 
representing the standard of care for metastatic pancreatic 
adenocarcinoma. Prior to FOLFIRINOX, 2 patients had 
received 6 cycles of gemcitabine (weekly), whereas 1 patient 
had undergone 5 cycles of gemcitabine + chloroquine (within 
a phase II clinical trial) only. Radiation therapy was admin-
istered to 3 (37.5%) patients prior to the CTC measurement 
(median, 30 Gy; range,  20-50 Gy). Surgical interventions 
had been conducted in 5 out of 8 patients (62.5%), with the 
majority of those being strictly palliative (Table II).
Figure 1. Representative images of circulating tumor cells (CTCs) detected 
with the CellTracks Analyzer II® after enrichment of whole blood samples 
using nanoparticles with an antibody directed against epithelial cell adhe-
sion molecule and subsequent staining with 4',6-diamidino-2-phenylindole 
(DAPI; for nuclei), the epithelial marker cytokeratin (CK) and the hematopo-
etic cell surface marker cluster of differentiation 45 (CD45). Nucleated cells 
that stained positive for CK and negative for CD45 were counted as CTCs. 
PE, phycoerythrin; APC, antigen-presenting cell.
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Detection of CTCs. CTCs were detected (CTC count ≥1/7.5 ml 
of blood) in the circulation of only 1 out of the 8 patients with 
AEGJ (12.5% of total; median CTC count of 3/7.5 ml of blood; 
Table I). However, CTCs were detected in 7 out of 8 patients 
(87.5%) with pancreatic adenocarcinoma, where a median 
overall CTC count of 4.5/7.5 ml of blood (range, 0-83/7.5 ml 
of blood; Table II) was recorded (Fig. 2).
Discussion
Thus far, the CellSearch® device has only been approved by 
the FDA for the detection of CTCs and as a prognostic tool 
to predict PFS and OS times in metastatic breast, colon and 
prostate cancer (14). However, as there is only limited litera-
ture available regarding the use of CellSearch® in patients with 
esophagogastric or pancreatic cancer (15-18), the present 
study aimed to determine whether CTCs are detectable by the 
CellSearch® system in these particular patient groups. AEGJ 
and pancreatic cancer were chosen due to their epithelial 
cell characteristic, an increasing incidence in the Western 
world and the rather high mortality even after surgical and/or 
chemotherapeutic treatments. Therefore, developing a prog-
nostic tool would be of high clinical importance, maybe even 
in order to guide therapeutic decisions. CTCs were identified 
in 7 out of 8 pancreatic cancer patients (87.5%), while detec-
tion of CTCs originating from an AEGJ was only possible in 
1 out of 8 patients (12.5%). The current study, even though the 
number of subjects included was low, offered the advantage of 
no inclusion bias, as the patients were randomly screened. At 
the same time, it allowed a 1:1 comparison of the two tumor 
entities. CTCs were determined using one single device under 
similar circumstances within the same period of time at a 
single university center.
The impact of the presence of CTCs in the circulation on 
patient outcome and survival has been studied extensively 
over the last years. A recently published meta-analysis pooling 
>6,800 patients investigated the prognostic value of CTCs in 
breast cancer (19): CTCs were associated with an increased 
risk of recurrence of the disease [hazard ratio (HR), 2.86; 
95% confidence interval (CI), 2.19‑3.75] and with significantly 
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Figure 2. Scatter plot of the number of ciculating tumor cells (CTCs) found in 
7.5 ml of blood drawn from patients with either esophagogastric or pancreatic 
adenocarcinoma. Horizontal lines indicate the median number of CTCs.
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higher mortality rates (HR, 2.78; 95% CI, 2.22-3.48). The 
analysis also provided evidence that the presence of CTCs 
was associated with a poorer prognosis in early-stage and 
metastatic breast cancer, regardless of the detection method 
[CellSearch® assay or reverse-transcriptase polymerase chain 
reaction (RT‑PCR)] (19). There have been numerous studies 
trying to determine a cutoff-value for the CTC count as a 
prognostic decision point. Studies have suggested a CTC 
count of ≥5/7.5 ml of blood to be valid for metastatic breast 
cancer (11,20), and a count of ≥3/7.5 ml of blood for metastatic 
colorectal cancer (21). However, the statistical determination 
method of these cutoff-values along with their prognostic and 
clinical importance are sources of controversy (22).
Thus far, the detection of CTCs in the circulation of 
patients with AEGJ has been based on anecdotal findings and 
case reports (15). A recent study reported the successful detec-
tion of CTCs (≥2 CTCs/7.5 ml of blood) in 8 out of 18 patients 
(44.4%) with gastric or esophageal cancer (16), which could 
not be confirmed by the present small series. Notably, the only 
patient who tested positive in the current study presented with 
distant metastases, whereas CTCs could not be detected in any 
of the 6 patients staged M0 [in accordance with the TNM clas-
sification (3)]. We may therefore hypothesize that the stage of 
the disease could have an impact on the detection (or even the 
presence) of CTCs in patients with AEGJ. This would also be 
in accordance with the results of a recent study in patients with 
esophageal squamous cell carcinoma demonstrating a correla-
tion between the stage of the disease, the presence of distant 
metastasis and the detection of CTCs (16), which has also been 
shown in patients with colorectal cancer (23).
For pancreatic cancer, there are also only a few studies 
evaluating CTCs. There is certain supporting evidence that 
CTCs originating from pancreatic adenocarcinoma can not 
only be detected, but may have a prognostic value as well (17): 
Kurihara et al (17) clearly showed a correlation between 
survival times and the presence of CTCs (≥1 CTC/7.5 ml 
of blood) in patients with advanced pancreatic carcinoma: 
In cases where CTCs were detected, patients with disease 
stage IV had a mean survival time of only 53 days, as opposed 
to 308 days for the CTC-negative patients (0 CTCs/7.5 ml of 
blood). Notably, the patient with the highest number of CTCs 
(105 CTCs/7.5 ml of blood) succumbed to the disease 5 days 
after the measurement. In the present study, the highest CTC 
value found was 83 CTCs/7.5 ml of blood. This patient also 
succumbed to the disease 4 days after the CTC measurement.
In a larger study (79 patients), Bidard et al (18) not only 
showed that CTC-positive patients with locally advanced 
pancreatic cancer (tested prior to and after chemotherapy) 
experienced shorter survival times, but also that the tumors 
of these patients were poorly-differentiated compared with 
those of CTC-negative patients. It has been shown that 
pancreatic endocrine tumors usually present with a relatively 
stable expression of EpCAM, thus making it possible to detect 
CTCs of these tumors with any EpCAM-based enrichment 
method (24).
A recent study has suggested that the site where the blood 
for CTC determination is drawn could also be of importance. 
Patients undergoing surgery for pancreatic cancer who 
presented with CTCs in portal venous blood exhibited a signif-
icantly higher rate of liver metastases 3 years after surgery 
compared with CTC-negative patients, whereas the presence 
of CTCs in the systemic circulation had no impact (25).
However, it is possible that CTCs escape the detection 
process, even in patients with advanced and metastatic disease, 
due to a loss in EpCAM expression, e.g., as found in breast 
cancer (26). This downregulation of EpCAM expression by 
CTCs is most likely due to the process of epithelial-to-mesen-
chymal transition (27), which is a crucial step during the 
process of the liberation of CTCs into the circulation (28). 
This may also explain the fact that the detection rate of CTCs 
differs significantly between the different methods used. The 
isolation by size of epithelial tumors technique, which is 
based on the filtration of cellular blood components through 
a membrane microfilter device (29), was able to detect CTCs 
originating from pancreatic adenocarcinomas not only more 
frequently, but also at higher numbers than the CellSearch® 
system [frequency, 93 vs. 40%; median, 9 CTCs/7.5 ml of 
blood (range, 0-240) vs. 0 CTCs/7.5 ml of blood (range, 0-144, 
respectively) (30). Similar findings were reported for CTCs 
from esophagogastric adenocarcinoma, where another 
size-based enrichment method (MetaCell®) was able to detect 
CTCs in 15 out of 20 patients (75.0%) (31).
The number of patients included in the present preliminary 
study was small (n=8). It was chosen based on a reasonable 
balance between cost effectiveness and the opportunity 
to test our hypothesis. No solid conclusions can therefore 
be drawn from this finding in comparison with previous 
studies reporting larger sample sizes ranging from 16 to 
79 patients (17,18,25,30,32). However, this was also not the 
overall goal of this study. Instead, the study aimed to evaluate 
whether it is generally possible to detect CTCs in patients with 
either AEGJ or pancreatic adenocarcinoma, regardless of the 
stage of the disease. In addition, due to the randomly screened 
nature and the fact that patients were chosen at various stages of 
the respective disease, any form of inclusion bias can definitely 
be excluded for the current study, which clearly demonstrates 
that CTCs originating from pancreatic adenocarcinoma can 
be detected by the CellSearch® device at various stages of 
the disease. A direct comparison between the detection rates 
of CTCs in the AEGJ and pancreatic patients in the present 
study may be inadequate, as the two groups were different in 
terms of the stage of the disease (only 2 out of 8 AEGJ patients 
with distant metastases vs. 4 out of 8 patients in the pancreatic 
cancer group). However, it can be concluded that the detection 
of CTCs in patients with AEGJ at early stages may be difficult.
Due to the small number of patients in the present study, we 
can only speculate about a correlation between the presence 
and detection of CTCs in these patients with the stage of the 
disease. Therefore, the feasibility of the CellSearch® system 
for this particular type of cancer remains questionable at this 
point. Recent studies in combination with the results from the 
present study suggest that size‑based filtration methods may 
be superior to the CellSearch® method for the detection of 
CTCs in patients with esophagogastric cancer (31).
Despite its limitations, CellSearch® offers a good method 
for the detection of CTCs in several tumor entities. In addi-
tion to the FDA-approved application in breast, colorectal and 
prostate cancer, the present study underlines the possibility 
that pancreatic adenocarcinoma may be another tumor entity 
with solid CTC detection rates (17). The main advantage of 
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the system is its easy practicability: the blood sample can be 
stored up to 96 h at room temperature. In addition, the majority 
of the steps during the detection are automated and therefore 
less prone to human error. This clearly offers the possibility 
of performing large multicenter trials. However, as already 
discussed, the price for this increase in practicability may be 
a loss in sensitivity when compared with size‑based filtration 
methods (30) or RT-PCR (33).
In summary, the results of this small pilot study may be 
important for the design of future studies with regard to the 
number of patients to be included. The preliminary data for 
this observational feasibility study suggested that the Cell-
Search® system may become a valuable tool for the detection 
of CTCs in patients with pancreatic adenocarcinoma, whereas 
the usefulness in patients with early-stage esophagogastric 
adenocarcinoma may be limited. While large trials focusing 
on patients with pancreatic adenocarcinomas may be feasible, 
further pilot studies are warranted for esophagogastric tumors. 
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